Medicis Hits Ranbaxy With Acne Drug Patent Suit

Law360, New York (June 12, 2009, 12:00 AM EDT) -- In its ongoing bid to protect Solodyn from generic competitors, skin health specialist Medicis Pharmaceutical Corp. has accused Indian generics maker Ranbaxy Laboratories Ltd. of infringing a patent for the popular acne medication.

The complaint, filed Thursday in the U.S. District Court for the District of Delaware, alleges that an abbreviated new drug application Ranbaxy Labs filed with the U.S. Food and Drug Administration seeking to make and sell an extended-release generic version of the acne drug infringes Medicis' patent.

The patent, which issued in 1999,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.